Neuroone Medical Technologies is trading 10.34% up at $2.24, although no company-specific catalyst for August 24, 2026 has been confirmed.
- Recent coverage cited fiscal third-quarter revenue growth of 16%, stronger orders, and a $1.7 million backlog, alongside wider losses and cash concerns; those results were released earlier.
- The broader market is mixed and generally weaker, so index-wide sentiment does not clearly explain the gain; confidence remains low pending a fresh announcement or filing.